Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 99 articles: HTML format Text format

Single Articles

August 2019
1. BHATTARAI S, Klimov S, Aleskandarany MA, Burrell H, et al
   Machine learning-based prediction of breast cancer growth rate in vivo.
   Br J Cancer. 2019 Aug 9. pii: 10.1038/s41416-019-0539.
   PubMed     Text format     Abstract available
   
   
   
2. HARVIE M, Pegington M, McMullan D, Bundred N, et al
   The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.
   Br J Cancer. 2019 Aug 1. pii: 10.1038/s41416-019-0522.
   PubMed     Text format     Abstract available
   
   
   July 2019
3. MUNZONE E, Bagnardi V, Campenni G, Mazzocco K, et al
   Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines.
   Br J Cancer. 2019 Jul 15. pii: 10.1038/s41416-019-0520.
   PubMed     Text format     Abstract available
   
   
   
4. LEE DW, Ryu HS, Jin MS, Lee KH, et al
   Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients.
   Br J Cancer. 2019 Jul 11. pii: 10.1038/s41416-019-0511.
   PubMed     Text format     Abstract available
   
   
   June 2019
5. CAPULLI M, Hristova D, Valbret Z, Carys K, et al
   Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry.
   Br J Cancer. 2019 Jun 26. pii: 10.1038/s41416-019-0501.
   PubMed     Text format     Abstract available
   
   
   May 2019
6. JONES ME, Schoemaker MJ, McFadden EC, Wright LB, et al
   Night shift work and risk of breast cancer in women: the Generations Study cohort.
   Br J Cancer. 2019 May 29. pii: 10.1038/s41416-019-0485.
   PubMed     Text format     Abstract available
   
   
   
7. KUROZUMI S, Joseph C, Sonbul S, Alsaeed S, et al
   A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.
   Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0486.
   PubMed     Text format     Abstract available
   
   
   
8. LOURO J, Posso M, Hilton Boon M, Roman M, et al
   A systematic review and quality assessment of individualised breast cancer risk prediction models.
   Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0476.
   PubMed     Text format     Abstract available
   
   
   
9. LIM B, Murthy RK, Lee J, Jackson SA, et al
   A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
   Br J Cancer. 2019 May 17. pii: 10.1038/s41416-019-0473.
   PubMed     Text format     Abstract available
   
   
   April 2019
10. DAULAT AM, Finetti P, Revinski D, Silveira Wagner M, et al
    ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.
    Br J Cancer. 2019 Apr 11. pii: 10.1038/s41416-019-0448.
    PubMed     Text format     Abstract available
    
    
    
11. RIBI K, Luo W, Colleoni M, Karlsson P, et al
    Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
    Br J Cancer. 2019 Apr 10. pii: 10.1038/s41416-019-0435.
    PubMed     Text format     Abstract available
    
    
    February 2019
12. ABDEL-FATAH TMA, Broom RJ, Lu J, Moseley PM, et al
    SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
    Br J Cancer. 2019 Feb 28. pii: 10.1038/s41416-019-0405.
    PubMed     Text format     Abstract available
    
    
    
13. LI N, Kong J, Lin Z, Yang Y, et al
    Ezrin promotes breast cancer progression by modulating AKT signals.
    Br J Cancer. 2019 Feb 26. pii: 10.1038/s41416-019-0383.
    PubMed     Text format     Abstract available
    
    
    
14. MEJDAHL MK, Wohlfahrt J, Holm M, Balslev E, et al
    Breast cancer mortality in synchronous bilateral breast cancer patients.
    Br J Cancer. 2019 Feb 26. pii: 10.1038/s41416-019-0403.
    PubMed     Text format     Abstract available
    
    
    
15. ESCALA-GARCIA M, Guo Q, Dork T, Canisius S, et al
    Genome-wide association study of germline variants and breast cancer-specific mortality.
    Br J Cancer. 2019 Feb 21. pii: 10.1038/s41416-019-0393.
    PubMed     Text format     Abstract available
    
    
    
16. MILEVSKIY MJG, Gujral U, Del Lama Marques C, Stone A, et al
    MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer.
    Br J Cancer. 2019 Feb 20. pii: 10.1038/s41416-019-0395.
    PubMed     Text format     Abstract available
    
    
    
17. FUJIWARA Y, Mukai H, Saeki T, Ro J, et al
    A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
    Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-019-0391.
    PubMed     Text format     Abstract available
    
    
    
18. METCALFE K, Lynch HT, Foulkes WD, Tung N, et al
    Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
    Br J Cancer. 2019 Feb 6. pii: 10.1038/s41416-019-0376.
    PubMed     Text format     Abstract available
    
    
    January 2019
19. OWEN LJ, Monaghan PJ, Armstrong A, Keevil BG, et al
    Oestradiol measurement during fulvestrant treatment for breast cancer.
    Br J Cancer. 2019 Jan 25. pii: 10.1038/s41416-019-0378.
    PubMed     Text format     Abstract available
    
    
    
20. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Text format     Abstract available
    
    
    
21. EGGEMANN H, Bernreiter AL, Reinisch M, Loibl S, et al
    Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0369.
    PubMed     Text format     Abstract available
    
    
    December 2018
22. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 Dec 25. pii: 10.1038/s41416-018-0344.
    PubMed     Text format    
    
    
    
23. KYBA CCM, Spitschan M
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study'.
    Br J Cancer. 2018 Dec 25. pii: 10.1038/s41416-018-0203.
    PubMed     Text format    
    
    
    
24. PEGRAM MD, Bondarenko I, Zorzetto MMC, Hingmire S, et al
    PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
    Br J Cancer. 2018 Dec 20. pii: 10.1038/s41416-018-0340.
    PubMed     Text format     Abstract available
    
    
    
25. ROMAN M, Hofvind S, von Euler-Chelpin M, Castells X, et al
    Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts.
    Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0358.
    PubMed     Text format     Abstract available
    
    
    
26. LOPEZ-KNOWLES E, Pearson A, Schuster G, Gellert P, et al
    Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
    Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0345.
    PubMed     Text format     Abstract available
    
    
    November 2018
27. TIAN J, Raffa FA, Dai M, Moamer A, et al
    Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0287.
    PubMed     Text format     Abstract available
    
    
    
28. GIANNAKEAS V, Cadarette SM, Ban JK, Lipscombe L, et al
    Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0225.
    PubMed     Text format     Abstract available
    
    
    
29. SNELL CE, Gough M, Liu C, Middleton K, et al
    Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-alpha and progesterone receptor-b.
    Br J Cancer. 2018 Nov 9. pii: 10.1038/s41416-018-0331.
    PubMed     Text format     Abstract available
    
    
    October 2018
30. MCGREGOR RJ, Chau YY, Kendall TJ, Artibani M, et al
    WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer.
    Br J Cancer. 2018 Oct 30. pii: 10.1038/s41416-018-0317.
    PubMed     Text format     Abstract available
    
    
    
31. MUNSTER P, Krop IE, LoRusso P, Ma C, et al
    Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
    Br J Cancer. 2018 Oct 26. pii: 10.1038/s41416-018-0235.
    PubMed     Text format     Abstract available
    
    
    
32. TAMBOUR M, Holt M, Speyer A, Christensen R, et al
    Manual lymphatic drainage adds no further volume reduction to Complete Decongestive Therapy on breast cancer-related lymphoedema: a multicentre, randomised, single-blind trial.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0306.
    PubMed     Text format     Abstract available
    
    
    
33. BERTUCCI F, Finetti P, Simeone I, Hendrickx W, et al
    The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0309.
    PubMed     Text format     Abstract available
    
    
    
34. LANGBALLE R, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Statin use and risk of contralateral breast cancer: a nationwide cohort study.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0252.
    PubMed     Text format     Abstract available
    
    
    
35. WALASZEK K, Lower EE, Ziolkowski P, Weber GF, et al
    Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0228.
    PubMed     Text format     Abstract available
    
    
    
36. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0177.
    PubMed     Text format    
    
    
    
37. SCIMECA M, Urbano N, Bonfiglio R, Schillaci O, et al
    Breast osteoblast-like cells: a new biomarker for the management of breast cancer.
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0255.
    PubMed     Text format     Abstract available
    
    
    
38. MEURS CJC, van Rosmalen J, Menke-Pluijmers MBE, Ter Braak BPM, et al
    A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers.
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0276.
    PubMed     Text format     Abstract available
    
    
    
39. CHAKRABORTY S, Jiang C, Gau D, Oddo M, et al
    Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0284.
    PubMed     Text format     Abstract available
    
    
    
40. O'CARRIGAN B, Lim JSJ, Jalil A, Harris SJ, et al
    Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0290.
    PubMed     Text format     Abstract available
    
    
    
41. BAJOR M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, et al
    Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0263.
    PubMed     Text format     Abstract available
    
    
    
42. KRUGER DT, Beelen KJ, Opdam M, Sanders J, et al
    Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0221.
    PubMed     Text format     Abstract available
    
    
    
43. STEVENS RG
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 Oct 3. pii: 10.1038/s41416-018-0058.
    PubMed     Text format    
    
    
    
44. BECKWITT CH, Clark AM, Ma B, Whaley D, et al
    Statins attenuate outgrowth of breast cancer metastases.
    Br J Cancer. 2018;119:1094-1105.
    PubMed     Text format     Abstract available
    
    
    
45. MADSSEN TS, Thune I, Flote VG, Lundgren S, et al
    Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment.
    Br J Cancer. 2018;119:1144-1154.
    PubMed     Text format     Abstract available
    
    
    September 2018
46. GRAY E, Marti J, Brewster DH, Wyatt JC, et al
    Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data.
    Br J Cancer. 2018 Sep 17. pii: 10.1038/s41416-018-0256.
    PubMed     Text format     Abstract available
    
    
    August 2018
47. BOEKEL NB, Jacobse JN, Schaapveld M, Hooning MJ, et al
    Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.
    Br J Cancer. 2018 Aug 1. pii: 10.1038/s41416-018-0159.
    PubMed     Text format     Abstract available
    
    
    July 2018
48. SAHA A, Harowicz MR, Grimm LJ, Kim CE, et al
    A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0185.
    PubMed     Text format     Abstract available
    
    
    
49. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
    Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0197.
    PubMed     Text format     Abstract available
    
    
    
50. LAMMERS PE, Dank M, Masetti R, Abbas R, et al
    Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.
    Br J Cancer. 2018 Jul 13. pii: 10.1038/s41416-018-0147.
    PubMed     Text format     Abstract available
    
    
    
51. STERLE HA, Nicoud MB, Massari NA, Taquez Delgado MA, et al
    Immunomodulatory role of histamine H4 receptor in breast cancer.
    Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0173.
    PubMed     Text format     Abstract available
    
    
    June 2018
52. LO LL, Milne RL, Liao Y, Cuzick J, et al
    Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.
    Br J Cancer. 2018 Jun 21. pii: 10.1038/s41416-018-0120.
    PubMed     Text format     Abstract available
    
    
    
53. CHERIYATH V, Kaur J, Davenport A, Khalel A, et al
    G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0137.
    PubMed     Text format     Abstract available
    
    
    
54. GUIU S, Mollevi C, Charon-Barra C, Boissiere F, et al
    Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
    Br J Cancer. 2018 Jun 8. pii: 10.1038/s41416-018-0142.
    PubMed     Text format     Abstract available
    
    
    
55. DERKS MGM, Bastiaannet E, Kiderlen M, Hilling DE, et al
    Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group.
    Br J Cancer. 2018 Jun 7. pii: 10.1038/s41416-018-0090.
    PubMed     Text format     Abstract available
    
    
    
56. ROHAN TE, Miller CA, Li T, Wang Y, et al
    Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0089.
    PubMed     Text format     Abstract available
    
    
    
57. TUNG NM, Garber JE
    BRCA1/2 testing: therapeutic implications for breast cancer management.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
    PubMed     Text format     Abstract available
    
    
    
58. HALKETT G, O'Connor M, Jefford M, Aranda S, et al
    RT Prepare: a radiation therapist-delivered intervention reduces psychological distress in women with breast cancer referred for radiotherapy.
    Br J Cancer. 2018 Jun 1. pii: 10.1038/s41416-018-0112.
    PubMed     Text format     Abstract available
    
    
    May 2018
59. WEIN L, Luen SJ, Savas P, Salgado R, et al
    Checkpoint blockade in the treatment of breast cancer: current status and future directions.
    Br J Cancer. 2018 May 29. pii: 10.1038/s41416-018-0126.
    PubMed     Text format     Abstract available
    
    
    
60. GULLO G, Walsh N, Fennelly D, Bose R, et al
    Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
    Br J Cancer. 2018 May 18. pii: 10.1038/s41416-018-0114.
    PubMed     Text format     Abstract available
    
    
    
61. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0092.
    PubMed     Text format    
    
    
    
62. MORTAZAVI SMJ
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0060.
    PubMed     Text format    
    
    
    
63. FRENCH DP, Southworth J, Howell A, Harvie M, et al
    Psychological impact of providing women with personalised 10-year breast cancer risk estimates.
    Br J Cancer. 2018 May 8. pii: 10.1038/s41416-018-0069.
    PubMed     Text format     Abstract available
    
    
    
64. CHEN S, Wang H, Li Z, You J, et al
    Interaction of WBP2 with ERalpha increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0119.
    PubMed     Text format     Abstract available
    
    
    
65. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
    Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
    PubMed     Text format     Abstract available
    
    
    April 2018
66. BHARTI R, Dey G, Das AK, Mandal M, et al
    Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0078.
    PubMed     Text format     Abstract available
    
    
    
67. ORECCHIONI S, Talarico G, Labanca V, Calleri A, et al
    Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0076.
    PubMed     Text format     Abstract available
    
    
    
68. LIIKANEN JS, Leidenius MH, Joensuu H, Vironen JH, et al
    Prognostic value of isolated tumour cells in sentinel lymph nodes in early-stage breast cancer: a prospective study.
    Br J Cancer. 2018 Apr 24. pii: 10.1038/s41416-018-0052.
    PubMed     Text format     Abstract available
    
    
    March 2018
69. JOSEPH C, Macnamara O, Craze M, Russell R, et al
    Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Br J Cancer. 2018 Mar 28. pii: 10.1038/s41416-018-0041.
    PubMed     Text format     Abstract available
    
    
    
70. QUIROS-GONZALEZ I, Tomaszewski MR, Aitken SJ, Ansel-Bollepalli L, et al
    Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry.
    Br J Cancer. 2018 Mar 26. pii: 10.1038/s41416-018-0033.
    PubMed     Text format     Abstract available
    
    
    
71. MCNAMARA KM, Guestini F, Sauer T, Touma J, et al
    In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics.
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0034.
    PubMed     Text format     Abstract available
    
    
    
72. GYORFFY B, Pongor L, Bottai G, Li X, et al
    An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0030.
    PubMed     Text format     Abstract available
    
    
    
73. EL ANSARI R, Craze ML, Diez-Rodriguez M, Nolan CC, et al
    The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
    Br J Cancer. 2018 Mar 16. pii: 10.1038/s41416-018-0038.
    PubMed     Text format     Abstract available
    
    
    
74. SAUERBREI W, Haeussler T
    Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0023.
    PubMed     Text format    
    
    
    
75. POUJADE FA, Mannion A, Brittain N, Theodosi A, et al
    WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0056.
    PubMed     Text format     Abstract available
    
    
    
76. PAPADAKIS ES, Reeves T, Robson NH, Maishman T, et al
    Reply to 'Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses''.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0032.
    PubMed     Text format    
    
    
    February 2018
77. REMSIK J, Fedr R, Navratil J, Bino L, et al
    Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.
    Br J Cancer. 2018 Feb 20. pii: bjc2017497. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
78. DOSS M
    Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure'.
    Br J Cancer. 2018 Feb 13. pii: bjc2017481. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    
79. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    Reply to 'Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure''.
    Br J Cancer. 2018 Feb 13. pii: bjc2017490. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    January 2018
80. LEGLER K, Rosprim R, Karius T, Eylmann K, et al
    Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017472. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
81. FOUKAKIS T, Lovrot J, Matikas A, Zerdes I, et al
    Immune gene expression and response to chemotherapy in advanced breast cancer.
    Br J Cancer. 2018 Jan 25. pii: bjc2017446. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
82. PLYM A, Bower H, Fredriksson I, Holmberg L, et al
    Loss in working years after a breast cancer diagnosis.
    Br J Cancer. 2018 Jan 23. pii: bjc2017456. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
83. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
    Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
    Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
84. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.
    Br J Cancer. 2018 Jan 23. pii: bjc2017359. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
85. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
    Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017437. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    December 2017
86. REDDY SM, Barcenas CH, Sinha AK, Hsu L, et al
    Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
    Br J Cancer. 2017 Dec 12. pii: bjc2017379. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    November 2017
87. CRAZE ML, Cheung H, Jewa N, Coimbra NDM, et al
    MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
    Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
88. NANDY SB, Orozco A, Lopez-Valdez R, Roberts R, et al
    Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis.
    Br J Cancer. 2017;117:1665-1675.
    PubMed     Text format     Abstract available
    
    
    
89. DANIELS B, Kiely BE, Houssami N, Lord SJ, et al
    Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    October 2017
90. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Text format     Abstract available
    
    
    
91. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    September 2017
92. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available
    
    
    
93. PONZETTI M, Capulli M, Angelucci A, Ventura L, et al
    Non-conventional role of haemoglobin beta in breast malignancy.
    Br J Cancer. 2017;117:994-1006.
    PubMed     Text format     Abstract available
    
    
    
94. MORRELL S, Roder D, Taylor R
    Reply to 'Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study''.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    
95. GREGOIRE C, Bragard I, Jerusalem G, Etienne AM, et al
    Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
96. YE ZJ, Qiu HZ, Liang MZ, Liu ML, et al
    Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
97. OSAKO T, Iwase T, Ushijima M, Yonekura R, et al
    A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
98. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Text format     Abstract available
    
    
    August 2017
99. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: